Back

Court rulings raise questions over Genencell’s COVID-19 treatment development

Verifying
  • Professor Kang founded Genencell and pursued ES16001 as a COVID-19 treatment.
  • Genencell recruited 109 patients, but only 100 participated before recruitment stopped.
  • The court ordered Genencell to pay CRO K 458 million Korean won; an appeal is pending.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.